Study Name: A 52-week, randomised, double-blind, placebo-controlled, parallelgroup, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype
Study Sponsor: GlaxoSmithKline Research & Development Limited
Indication: Severe Uncontrolled Asthma with an Eosinophilic Phenotype
Study Coordinator: Janelle Gonzalez
Contact Number: (310) 853-8484 ext. 706
Study Status: Enrolling Soon!
Contact Us to learn more